StockNews.AI
HTGC
StockNews.AI
146 days

Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital

1. Hercules Capital provides Savara Inc. $200 million loan. 2. Capital supports Savara's FDA BLA submission for MOLBREEVI.

2m saved
Insight
Article

FAQ

Why Bullish?

The loan strengthens Savara's financial position, likely benefiting HTGC through increased loan demand. Historically, similar agreements have boosted reputation and stock performance for lenders.

How important is it?

HTGC's involvement in a significant loan can enhance its market visibility and attract further investments. The collaboration may also indicate trust in HTGC's lending capabilities, enhancing overall market perception.

Why Short Term?

The immediate impact stems from Savara's boosted liquidity and FDA progress, influencing HTGC right away. Past loan arrangements have shown quick benefits for lenders when their clients succeed.

Related Companies

SVRATCPCOXLC
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a tre.

Related News